Anoro▼ Ellipta umeclidinium/vilanterol

Product menu

Anoro is generally well tolerated1

Please refer to the SmPC for further information on the Anoro Ellipta safety profile prior to prescribing

Document icon

SEE THE SmPC

Support your patients starting on Anoro Ellipta maintenance therapy

Ellipta demonstration device

Demonstration device

Demonstration device for healthcare professionals to show patients how to use the Ellipta device correctly.

ORDER NOW
Nurse with senior patients

Provide patient resources

Support your patients with an Ellipta information leaflet and additional COPD resources.

ORDER NOW
Ellipta Whistle Trainer

Ellipta inhalation trainer

For patients who have been prescribed an Ellipta inhaler, check their inhaler technique by ordering a training whistle.

ORDER NOW
You might also be interested in…

Head-to-head data vs. a LAMA

Dosing & the Ellipta device

Molecules

NICE COPD Guidelines

References

  1. Anoro Ellipta SmPC

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

© 2021 GSK group of companies or its licensor.
ANORO was developed in collaboration with INNOVIVA.
Trademarks are owned by or licensed to the GSK group of companies.

Innoviva logo

PM-GB-UCV-WCNT-210002 V2.0 June 2021